


Database	Search strategy	Total
Pubmed	("IgA Glomerulonephritides" OR "IgA Glomerulonephritis" OR "IgA Nephropathy" OR "Berger Disease" OR "Immunoglobulin A Nephropathy" OR IgAN OR "IgA Type Nephritis") AND ("DuP 753" OR "MK 954" OR Losartan OR "Losartan potassium" OR "Angiotensin II Receptor Antagonist" OR "Angiotensin II Receptor blocker" OR ARB)	128
WOS	("IgA Glomerulonephritides" OR "IgA Glomerulonephritis" OR "IgA Nephropathy" OR "Berger Disease" OR "Immunoglobulin A Nephropathy" OR IgAN OR "IgA Type Nephritis") AND ("DuP 753" OR "MK 954" OR Losartan OR "Losartan potassium" OR "Angiotensin II Receptor Antagonist" OR "Angiotensin II Receptor blocker" OR ARB)	181
Scopus	TITLE-ABS-KEY((Losartan OR "Losartan potassium" OR Cozaar OR "Angiotensin II Receptor Antagonist" OR "Angiotensin II Receptor blocker" OR ARB) AND ("IGA Glomerulonephritis" OR "IGA Nephropathy" OR "Immunoglobulin A Nephropathy" OR "Berger Disease" OR "Immunoglobulin A Nephropathy" OR IgAN OR "IGA Type Nephritis"))	346
Ovid	("IgA Glomerulonephritides" OR "IgA Glomerulonephritis" OR "IgA Nephropathy" OR "Berger Disease" OR "Immunoglobulin A Nephropathy" OR IgAN OR "IgA Type Nephritis") AND ("DuP 753" OR "MK 954" OR Losartan OR "Losartan potassium" OR "Angiotensin II Receptor Antagonist" OR "Angiotensin II Receptor blocker" OR ARB)	3

Online Resource 1: Detailed search strategies of each database





Online Resource 2: PRISMA Flow Diagram


Online Resource 3. Baseline Characteristics and Intervention Details of Included Studies.

Study Name and Interventions		Sample Size	Age,yr, Mean (SD)	Gender, Male, N (%)	Office SBP (mmHg), Mean (SD)	Office DBP (mmHg), Mean (SD)	Mean blood pressure (mm Hg), Mean (SD)	Urinary protein excretion (g/d), Mean (SD)	Serum creatinine (mg/dl), Mean (SD)	Serum IgA (mg/dL)	eGFR (mL/min/1.73 m ²), Mean (SD)	Serum uric acid (micro mol/L), Mean (SD)	Creatinine clearance (mL/min/1.73 m ²), Mean (SD)
Xie et al.2011	Losartan	30	33.67 (11.62)	14 (46.7%)	NA	NA	101.13 (9.88)	1.12 (0.54)	0.88 (0.26)	NA	97.85 (32.87)	347.67 (104.05)	NA
	Mizoribine	35	33.63 (11.71)	14 (40.0%)	NA	NA	97.61 (8.54)	1.35 (0.74)	0.9 (0.25)	NA	95.63 (28.31)	312.58 (76.94)	NA
	Losartan + Mizoribine	34	33.68 (10.29)	14 (41.2%)	NA	NA	101.15 (9.94)	1.21 (0.56)	0.96 (0.37)	NA	91.50 (29.83)	335.44 (99.95)	NA
Russo et al. 2001	All Patients	10	25.0 (1.8)	4(40%)	118.5 (3.7)	75.9 (1.8)	90.1 (1.3)	1.52 (0.37)	NA	NA	NA	NA	109.6 (8.4)
Shimizu et al. 2008	Losartan	18	36.0 (8.5)	11(61.1%)	119.3 (10.3)	74.8 (7.5)	NA	0.81 (0.52)	1.0 (0.2)	267.3 (92.9)	72.0 (15.9)	374.72 (83.27)	NA
	Control (Anti-platelet)	18	35.7 (8.1)	6 (33.3%)	122.1 (9.6)	73.4 (12.1)	NA	0.73 (0.36)	0.9 (0.2)	334.7 (73.6)	75.4 (18.1)	368.78 (83.27)	NA
Park et al.2003	Losartan	20	39.3 (8.7)	9 (45%)	131 (16)	89 (9)	103 (10)	2.3 (1.5)	1.5 (0.6)	NA	63 (22)	380.67 (95.17)	63 (22)
	Amlodipine	16	44.3 (13.4)	9 (56.25%)	131 (12)	86 (11)	102 (9)	2.1 (0.7)	1.5 (0.6)	NA	63 (24)	422.31 (113.01)	63 (24)
Horita et al. 2004	Losartan	10	42.7 (12.0)	5 (50%)	124 (5)	80 (5)	94 (5)	0.81 (0.44)	0.88 (0.17)	NA	88.3 (19.8)	NA	88.3 (19.8)
	Temopcapril	10	39.6 (10.8)	4 (40%)	121 (8)	78 (8)	92 (8)	0.73 (0.36)	0.85 (0.21)	NA	92.5 (17.2)	NA	92.5 (17.2)
	Losartan + Temopcapril	11	39.6 (10.4)	5 (45.45%)	121 (9)	73 (11)	89 (10)	0.75 (0.30)	0.83 (0.19)	NA	91.5 (24.6)	NA	91.5 (24.6)
Horita et al.2006	Losartan	16	42 (36)	9 (56.25%)	123 (20)	80 (20)	NA	0.83 (1.76)	0.89 (0.56)	NA	88 (72.8)	NA	NA
	Temopcapril	14	43 (37.42)	8 (57.14%)	112 (29.93)	70 (29.93)	NA	0.60 (0.79)	0.84 (0.64)	NA	89.8 (85.68)	NA	NA
	Losartan + Temopcapril	13	38 (32.45)	7 (53.85%)	124 (25.24)	76 (36.1)	NA	0.80 (1.19)	0.8 (0.72)	NA	95.3 (80.76)	NA	NA
Horita et al.2007	Prednisone	18	32 (10)	8 (44.44%)	121 (7)	75 (7)	NA	1.6 (0.4)	0.7 (0.1)	366 (131)	NA	NA	103 (28)
	Losartan + Prednisone	20	34 (12)	12 (60%)	120 (8)	73 (6)	NA	1.6 (0.6)	0.8 (0.2)	258.3 (83.4)	NA	NA	104 (36)
Shima et al.2018	Lisinopril	31	11.9 (3.3)	16 (51.6%)	109.1 (12.5)	62.5 (10.6)	NA	NA	0.5 (0.1)	258.3 (83.4)	121 (14.6)	NA	NA

	Losartan + Lisinopril	31	12.0 (3.2)	18 (58.1%)	109 (12.1)	63.5 (8.9)	NA	NA	0.5 (0.1)	234.7 (89.2)	120.4 (15.8)	NA	NA
--	-----------------------	----	---------------	---------------	---------------	---------------	----	----	-----------	-----------------	--------------	----	----




(B)




Online Resource 4: Risk of Bias assessment using the ROB-2 tool, **(A)** Included Studies **(B):** Russo et al. 2001 (A crossover study).

(A)



(B)




(C)


Losartan	0.10 [-5.65to 5.85]	-1.00 [-8.47to 6.47]	-1.00 [-8.57to 6.57]	-1.00 [-8.02to 6.02]	-4.90 [-10.06to 0.26]
0.10 [-5.65to 5.85]	Losartan + Mizoribine	.	.	.	-5.00 [-10.10to 0.10]
-1.00 [-8.47to 6.47]	-1.10 [-10.52to 8.32]	Amlodipine	.	.	.
-1.00 [-8.57to 6.57]	-1.10 [-10.60to 8.40]	-0.00 [-10.63to10.63]	Temocapril	-0.00 [-9.02to 9.02]	.
-1.00 [-8.02to 6.02]	-1.10 [-10.18to 7.98]	-0.00 [-10.25to10.25]	-0.00 [-9.02to 9.02]	Losartan + Temocapril	.
-4.90 [-10.06to 0.26]	-5.00 [-10.10to 0.10]	-3.90 [-12.98to 5.18]	-3.90 [-13.06to 5.26]	-3.90 [-12.62to 4.82]	Mizoribine

Online Resource 5. Change from baseline in MBP at 3 months: (A) Network plot, (B) Network forest plot, (C) League table.

(A)



(B)




(C)


Losartan + Temocapril	-1.00 [-10.64to 8.64]	-3.00 [-10.59to 4.59]	.	.
-1.00 [-10.64to 8.64]	Temocapril	-2.00 [-10.13to 6.13]	.	.
-3.00 [-10.59to 4.59]	-2.00 [-10.13to 6.13]	Losartan	-0.68 [-6.36to 5.00]	-6.17 [-11.49to-0.85]
-3.68 [-13.16to 5.80]	-2.68 [-12.59to 7.23]	-0.68 [-6.36to 5.00]	Losartan + Mizoribine	-5.49 [-10.85to-0.13]
-9.17 [-18.44to 0.10]	-8.17 [-17.88to 1.54]	-6.17 [-11.49to-0.85]	-5.49 [-10.85to-0.13]	Mizoribine

Online Resource 6. Change from baseline in MBP at 6 months: (A) Network plot, (B) Network forest plot, (C) League table.

(A)



(B)




(C)


Losartan	-0.00 [-0.53to0.53]	-0.06 [-0.28to0.16]	-0.09 [-0.33to0.15]
0.00 [-0.53to0.53]	Amlodipine	.	.
-0.06 [-0.28to0.16]	-0.06 [-0.63to0.51]	Losartan + Temocapril	-0.03 [-0.28to0.22]
-0.09 [-0.33to0.15]	-0.09 [-0.67to0.49]	-0.03 [-0.28to0.22]	Temocapril

Online Resource 7. Change from baseline in serum creatinine at 3 months: (A) Network plot, (B) Network forest plot, (C) League table.

(A)



(B)




(C)


Temocapril	-2.30 [-39.17to34.57]	.	-15.80 [-60.32to28.72]
-2.30 [-39.17to34.57]	Losartan	-3.20 [-33.42to27.02]	-13.50 [-50.27to23.27]
-5.50 [-53.17to42.17]	-3.20 [-33.42to27.02]	Antiplatelet	.
-15.80 [-60.32to28.72]	-13.50 [-50.27to23.27]	-10.30 [-57.90to37.30]	Losartan + Temocapril

Online Resource 8. Change from baseline in plasma aldosterone at 12 months: (A) network plot, (B) network forest plot, (C) League table.

(A)



(B)




(C)


Losartan	-0.00 [-0.65to0.65]	-0.86 [-3.37to1.65]	-1.05 [-3.63to1.53]	
0.00 [-0.65to0.65]	Antiplatelet	.	.	
-0.86 [-3.37to1.65]	-0.86 [-3.45to1.73]	Losartan + Temocapril	-0.19 [-3.19to2.81]	
-1.05 [-3.63to1.53]	-1.05 [-3.72to1.62]	-0.19 [-3.19to2.81]	Temocapril	

Online Resource 9. Change from baseline in plasma renin at 12 months: (A) Network plot, (B) Network forest plot, (C) League table.

(A)



(B)




(C)


Mizoribine	0.96 [-15.51to17.43]	3.29 [-13.92to20.50]	.	.	
0.96 [-15.51to17.43]	Losartan + Mizoribine	2.33 [-16.32to20.98]	.	.	
3.29 [-13.92to20.50]	2.33 [-16.32to20.98]	Losartan	4.10 [-21.03to29.23]	5.30 [-14.90to25.50]	
7.39 [-23.07to37.85]	6.43 [-24.86to37.72]	4.10 [-21.03to29.23]	Losartan + Temocapril	1.20 [-22.90to25.30]	
8.59 [-17.95to35.13]	7.63 [-19.86to35.12]	5.30 [-14.90to25.50]	1.20 [-22.90to25.30]	Temocapril	

Online Resource 10. Change from baseline in eGFR at 3 months: (A) network plot, (B) network forest plot, (C) League table.


(A)



(B)




(C)




Online Resource 11. Rankograms for: (A) SBP at 3 months, (B) SBP at 6 months, (C) SBP at 12 months.


(A)



(B)




(C)




Online Resource 12. Rankograms for: (A) DBP at 3 months, (B) DBP at 6 months, (C) DBP at 12 months.


(A)




(B)




(C)



Online Resource 13. Rankograms for urinary protein excretion at: (A) 3 months, (B) 6 months, (C) 12 months.



Online Resource 14. Rankograms for **(A)** MBP at 3 months, **(B)** MBP at 6 months, **(C)** Serum creatinine at 3 months.



Online Resource 15. Rankograms for **(A)** eGFR at 3 months, **(B)** Plasma Aldosterone concentration at 12 months, **(C)** Plasma Renin activity at 12 months.